Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2011

View Archived Issues

Intranasal PH-94B spray reduces anxiety in women with social anxiety disorder

GI-4000 is immunogenic in phase IIa consolidation therapy trial in stage I-III NSCLC

Promising preclinical data reported on new HIV vaccine based on lumpy skin disease virus

Amgen designs novel beta-secretase 1 inhibitors for cognition disorders

Bayer Schering Pharma presents new cancer diagnostic imaging agents

New melanocortin MC1 receptor agonists synthesized

Neuralstem cleared to dose final cohort in ongoing phase Ia NSI-189 trial

Threshold Pharmaceuticals completes enrollment in phase II TH-302 pancreatic cancer trial

Cel-Sci's anticancer drug Multikine lowers cholesterol in phase II trials

GC-33 is safe in hepatocellular carcinoma in first-in-human study

TriMix-DC vaccine is safe and immunogenic in phase I trial in pretreated melanoma

Algeta receives grant to develop novel tumor-targeted thorium conjugates

MicroRNA-155 may be a marker of metabolic syndrome

New antibacterial FabI inhibitors synthesized by FAB Pharma

Yissum Research Development patents new cannabinoid CB2 receptor ligands

Seaside Therapeutics begins phase IIb STX-209 trial in autism spectrum disorders

Luminex to acquire EraGen Biosciences

Merck KGaA discontinues approval process for cladribine tablets in MS

Abbott and Biotest enter agreement to develop and commercialize BT-06 for autoimmune diseases

FDA approves CorMedix's SPA for phase III CRMD-001 trial

Achillion begins dosing in second segment of phase IIa ACH-1625 trial in chronic hepatitis C

Infinity Pharmaceuticals expands development program for anticancer agent IPI-926

Ligand Pharmaceuticals to advance Captisol-enabled melphalan program

NanoBio starts phase Ib trial of intranasal influenza vaccine

FDA approves personalized cell therapy laViv to improve appearance of smile lines

Enrollment begins in phase II RP-G28 trial in patients with lactose intolerance